Log in

Relevant bibliographies by topics / Rheumatology and arthritis / Journal articles

Journal articles on the topic 'Rheumatology and arthritis'

To see the other types of publications on this topic, follow the link: Rheumatology and arthritis.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Rheumatology and arthritis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Baillet, Athan, Candice Trocmé, Xavier Romand, Chuong M. V. Nguyen, Anais Courtier, Bertrand Toussaint, Philippe Gaudin, and Olivier Epaulard. "Calprotectin discriminates septic arthritis from pseudogout and rheumatoid arthritis." Rheumatology 58, no. 9 (March 28, 2019): 1644–48. http://dx.doi.org/10.1093/rheumatology/kez098.

Full text

Abstract:

Abstract Objective We aimed to determine whether calprotectin and α-defensins could discriminate septic from other inflammatory arthritides. Methods Synovial fluids with a predominance of neutrophils from patients with septic arthritis, pseudogout and RA were prospectively collected. Neutrophil-related proteins calprotectin and human neutrophil α-defensins levels were assessed in synovial fluids. Demographic parameters and biomarkers with P-value ⩽0.05 for differentiating septic from non-septic arthritis were included in a multivariable model. Multivariable logistic regression with stepwise selection was performed to build the final combined model. Results A total of 74 patients were included: septic arthritis (n = 26), pseudogout (n = 28) and RA (n = 20). Patients with septic arthritis were more likely to be male and young, and to display higher synovial neutrophil count. Calprotectin was significantly increased in patients with septic arthritis. The multivariable model included calprotectin, synovial fluid neutrophil count and gender. Calprotectin was the only biomarker that discriminated septic arthritis from non-septic inflammatory arthritides, with 76% sensitivity, 94% specificity and a positive likelihood ratio = 12.2 at the threshold for calprotectin of 150 mg/l. Conclusion Synovial fluid calprotectin is a relevant biomarker to discriminate septic arthritis from other inflammatory arthritides. This biomarker should be tested in an independent cohort.

APA, Harvard, Vancouver, ISO, and other styles

2

ODEWUSI, OO, MJ ABDULMUMIN, and OO OLANIYAN. "AN ASSESSMENT OF AUTOIMMUNITY IN ARTHRITIS PATIENTS." International Journal of Medical Laboratory Research 07, no. 01 (2022): 53–61. http://dx.doi.org/10.35503/ijmlr.2022.7108.

Full text

Abstract:

Objectives: The goal of this study is to estimate autoimmune biomarkers that characterize the development and severity of arthritis, but probably normalize following successful therapy. Materials and methods: In this study a total of 109 subjects were used out of which treated and untreated arthritics were 48 and 44 respectively, the remaining 17 were healthy individuals which were used as control. Samples were collected from patients attending Rheumatology and Orthopedic clinic of Federal Teaching Hospital Ido-ekiti, Ekiti State Nigeria. Antinuclear antibody was estimated using Enzyme Linked Immunosorbent Assay (ELISA) while Lupus Erythematosus cells were ascertained microscopically using Leishman staining technique. All parameters were assessed in treated and untreated arthritic patients relative to healthy subjects. Body mass index was also calculated. Statistical analysis was done using SPSS. Results: Body mass index and Antinuclear antibodies were significantly higher in treated and untreated arthritics compared to control (P<0.05). When treated and untreated arthritics were compared, Body mass index and Antinuclear antibody were found to be significantly higher in untreated arthritics (P<0.05). Antinuclear antibody and Age correlated directly in untreated arthritics. Lupus Erythematosus cell prevalence was found to be higher in untreated arthritics having a percentage Lupus Erythematosus test positivity of 6.8% compared to the 2.1% seen in treated arthritics. Conclusion: It was found that Autoimmunity in arthritics can be significantly lowered through treatment with Arthritic drugs, diets, life style modifications over a period of time. The study suggests that Antinuclear antibody and Lupus Erythematosus estimations could be adopted as markers of diagnosis, prognosis and monitoring of arthritis.

APA, Harvard, Vancouver, ISO, and other styles

3

Samycia, Michael, Collette McCourt, Kam Shojania, and Sheila Au. "Experiences From a Combined Dermatology and Rheumatology Clinic." Journal of Cutaneous Medicine and Surgery 20, no. 5 (July 8, 2016): 486–89. http://dx.doi.org/10.1177/1203475416649138.

Full text

Abstract:

Background: The Dermatology and Rheumatology Treatment Clinic is a novel multidisciplinary clinic where patients are concomitantly assessed by a rheumatologist and dermatologist. Objectives: To determine the number of patients seen in clinic, patient demographics, and most common diagnoses. Method: A retrospective review was performed over a 2-year period. Data collected included patient age, sex, dermatologic diagnosis, rheumatologic diagnosis, biopsies performed, and number of follow-up visits. Results: A total of 320 patients were seen (78% female, 22% male). The most common rheumatologic diagnoses were systemic lupus erythematosus (18%), rheumatoid arthritis (15%), psoriatic arthritis (13%), and undifferentiated connective tissue disease (8%). The most common dermatologic diagnoses were dermatitis (17%), psoriasis (11%), cutaneous lupus (7%), various types of alopecia (6%), and infections (5%). Conclusions: Skin diagnoses were often unrelated to the underlying rheumatologic diagnosis. Rheumatologists and dermatologists can both benefit from being aware of the dermatologic conditions that rheumatologic patients are experiencing.

APA, Harvard, Vancouver, ISO, and other styles

4

Snaith, M. "Clinical Rheumatology: Established Rheumatoid Arthritis." Foot 10, no. 2 (June 2000): 113–14. http://dx.doi.org/10.1054/foot.2000.0598.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Iyer, Deepa, and Ernest Wong. "Images in rheumatology: “Accelerator” arthritis." Indian Journal of Rheumatology 6, no. 3 (September 2011): 148. http://dx.doi.org/10.1016/s0973-3698(11)60079-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kiely, Patrick D. W., and Mark E. Lloyd. "Ankle arthritis – an important signpost in rheumatologic practice." Rheumatology 60, no. 1 (October 24, 2020): 23–33. http://dx.doi.org/10.1093/rheumatology/keaa531.

Full text

Abstract:

Abstract Ankle arthritis is a useful clinical signpost to differential diagnosis in rheumatic disease. Biomechanical features and differences in cartilage physiology compared with the knee may confer protection of the ankle joint from factors predisposing to certain arthritides. The prevalence of ankle OA is low, and usually secondary to trauma. Primary OA of the ankle should be investigated for underlying causes, especially haemochromatosis. New presentations of inflammatory mono/oligo arthritis involving the ankle are more likely due to undifferentiated arthritis or spondyloarthritis than RA, and gout over CPPD. The ankle is often involved in bacterial and viral causes of septic arthritis, especially bacterial, chikungunya and HIV infection, but rarely tuberculosis. Periarticular hind foot swelling can be confused with ankle arthritis, exemplified by Lofgren’s syndrome and hypertrophic osteoarthropathy where swelling is due to subcutaneous oedema and osteitis respectively, and the ankle joint is rarely involved.

APA, Harvard, Vancouver, ISO, and other styles

7

Schwarting, Andreas. "Von ADAPTHERA zu Rheuma-VOR: Konzept der koordinierten Kooperation zur Verbesserung der rheumatologischen Versorgungsqualität." Aktuelle Rheumatologie 43, no. 05 (October 2018): 406–9. http://dx.doi.org/10.1055/a-0658-1031.

Full text

Abstract:

ZusammenfassungRheumatologische Erkrankungsbilder nehmen in Ihrer Relevanz immer weiter zu. Die Kombination aus einem optimalen Behandlungsbeginn innerhalb von 12 Wochen nach Beschwerdebeginn und dem Mangel an Rheumatologen stellt eine große Herausforderung für alle Beteiligten dar. Ein möglicher Ansatzpunkt ist die koordinierte Kooperation von Patienten, Primärversorgern (Internisten, Orthopäden, Dermatologen) und den niedergelassenen Rheumatologen mithilfe einer zentralen Koordinationsstelle. Das erfolgreich etablierte rheinland-pfalzweite Netzwerk ADAPTHERA konnte zeigen, dass durch Risikostratifizierung eine zeitnahe Diagnose der Rheumatoiden Arthritis möglich ist und dabei die Ressource „Rheumatologe“ geschont wird. Die durch den Innovationsfonds des Gemeinsamen Bundesausschusses geförderte Proof-of-Concept Folgestudie Rheuma-VOR fußt auf dem gleichen Prinzip, jedoch stehen nun 3 entzündlich-rheumatische Erkrankungen (Rheumatoide Arthritis, Psoriasis Arthritis und Spondylarthritis) im Fokus. Zudem wurde das Projekt auf die Bundesländer Rheinland-Pfalz, Niedersachsen und dem Saarland ausgeweitet. Das Ziel ist die Steigerung der Versorgungsqualität in den 3 Bundesländern bei gleichzeitiger Reduktion der Wartezeiten.

APA, Harvard, Vancouver, ISO, and other styles

8

Dorst, Daphne N., Mark Rijpkema, Marti Boss, Birgitte Walgreen, Monique M. A. Helsen, Desirée L. Bos, Maarten Brom, et al. "Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis." Rheumatology 59, no. 12 (July 30, 2020): 3952–60. http://dx.doi.org/10.1093/rheumatology/keaa295.

Full text

Abstract:

Abstract Objective In RA, synovial fibroblasts become activated. These cells express fibroblast activation protein (FAP) and contribute to the pathogenesis by producing cytokines, chemokines and proteases. Selective depletion in inflamed joints could therefore constitute a viable treatment option. To this end, we developed and tested a new therapeutic strategy based on the selective destruction of FAP-positive cells by targeted photodynamic therapy (tPDT) using the anti-FAP antibody 28H1 coupled to the photosensitizer IRDye700DX. Methods After conjugation of IRDye700DX to 28H1, the immunoreactive binding and specificity of the conjugate were determined. Subsequently, tPDT efficiency was established in vitro using a 3T3 cell line stably transfected with FAP. The biodistribution of [111In]In-DTPA-28H1 with and without IRDye700DX was assessed in healthy C57BL/6N mice and in C57BL/6N mice with antigen-induced arthritis. The potential of FAP-tPDT to induce targeted damage was determined ex vivo by treating knee joints from C57BL/6N mice with antigen-induced arthritis 24 h after injection of the conjugate. Finally, the effect of FAP-tPDT on arthritis development was determined in mice with collagen-induced arthritis. Results 28H1-700DX was able to efficiently induce FAP-specific cell death in vitro. Accumulation of the anti-FAP antibody in arthritic knee joints was not affected by conjugation with the photosensitizer. Arthritis development was moderately delayed in mice with collagen-induced arthritis after FAP-tPDT. Conclusion Here we demonstrate the feasibility of tPDT to selectively target and kill FAP-positive fibroblasts in vitro and modulate arthritis in vivo using a mouse model of RA. This approach may have therapeutic potential in (refractory) arthritis.

APA, Harvard, Vancouver, ISO, and other styles

9

Yehudina, Ye D., and S. А. Trypilka. "Paraneoplastic arthritis — at the crossroads of rheumatology and oncology." PAIN, JOINTS, SPINE 12, no. 1 (October 23, 2022): 23–29. http://dx.doi.org/10.22141/pjs.12.1.2022.325.

Full text

Abstract:

Paraneoplastic arthritides (PA) are a group of inflammatory arthropathies associated with latent or manifest malignancy, localized in a distant site in relation to the primary focus and caused by immune-mediated mechanisms. Although the pathogenesis of PA is unknown, immune-mediated mechanisms can cause paraneoplastic syndrome with a dominant feature of polyarthritis. Arthritis can be both the initial manifestation of the disease, and it can manifest itself some time before the oncological process. Common forms of PA include paraneoplastic oligo/polyarthritis; hypertrophic osteoarthropathy; remitting seronegative symmetric synovitis with pitting edema; palmar fasciitis and pancreatic panniculitis associated with pancreatic carcinoma. The purpose of this review article was to describe the clinical characteristics, diagnostic assessment and treatment of paraneoplastic arthritis, and highlight the challenges that healthcare professionals may face in order to distinguish these conditions from other autoimmune rheumatic diseases. Further research is needed to understand the mechanisms associated with PA and to develop new diagnostic biomarkers.

APA, Harvard, Vancouver, ISO, and other styles

10

Solomon, Daniel H., Richard J. Bucala, Mariana J. Kaplan, and Peter A. Nigrovic. "Arthritis & Rheumatology : Evolving to Meet the Challenges of Rheumatology." Arthritis & Rheumatology 72, no. 8 (June 8, 2020): 1254–55. http://dx.doi.org/10.1002/art.41303.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Keat, Andrew. "I71. Reactive Arthritis and Enteropathic Arthritis." Rheumatology 53, suppl_1 (April 2014): i15—i16. http://dx.doi.org/10.1093/rheumatology/keu067.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Southwood, T. R. "ABC of Rheumatology: ARTHRITIS IN CHILDREN." BMJ 310, no. 6981 (March 18, 1995): 728–32. http://dx.doi.org/10.1136/bmj.310.6981.728.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

AMOS, R. S., D. E. BAX, J. T. BOURNE, J. WINFIELD, and N. J. sheehan. "ARTHRITIS ARTEFACTA: FACTITIOUS DISEASE IN RHEUMATOLOGY." Rheumatology 30, no. 6 (1991): 455–58. http://dx.doi.org/10.1093/rheumatology/30.6.455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rozenfeld, Vitalina, Larisa Chagan, and Evgenia Kleyman. "The Year in Review: Rheumatology." Journal of Pharmacy Practice 14, no. 1 (February 2001): 54–69. http://dx.doi.org/10.1106/8wa6-f8na-hty5-h2gt.

Full text

Abstract:

Pharmacologic management of rheumatoid arthritis has been a subject of extensive research within the last several years. Novel nonsteroidal anti-inflammatory drugs have entered the arena offering equal efficacy with an improved toxicity profile. The selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, are described. New disease modifying antirheumatic drugs include leflunomide, etanercept, and infliximab. Methotrexate, a widely used antirheumatic agent, has been continuously studied with other disease modifying therapies, such as sulfasalazine, hydroxychloroquine, and cyclosporin. Therapeutic principles of rheumatoid arthritis therapy, as well as the role of new treatment modalities is discussed in this review.

APA, Harvard, Vancouver, ISO, and other styles

15

Wollenhaupt, J??rgen, and Henning Zeidler. "Undifferentiated arthritis and reactive arthritis." Current Opinion in Rheumatology 10, no. 4 (July 1998): 306–13. http://dx.doi.org/10.1097/00002281-199807000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Cobb, Kelly L., Enrique A. Mendez, and Luis R. Espinoza. "Gouty Arthritis Mimicking Rheumatoid Arthritis." JCR: Journal of Clinical Rheumatology 4, no. 4 (August 1998): 225–28. http://dx.doi.org/10.1097/00124743-199808000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Muravyev, Yu V., and A. S. Misiyuk. "Rheumatoid arthritis classification criteria: debatable problems." Rheumatology Science and Practice 56, no. 6 (January 22, 2019): 805–7. http://dx.doi.org/10.14412/1995-4484-2018-805-807.

Full text

Abstract:

The paper discusses the issues of imperfect 1987 American College of Rheumatology (ACR) and the 2010 ACR/European League Against Rheumatology (EULAR) rheumatoid arthritis classification criteria and justifies the need for their correction.

APA, Harvard, Vancouver, ISO, and other styles

18

HAZES, J. M. W., and A. J. SILMAN. "RHEUMATOID ARTHRITIS." Rheumatology 29, no. 4 (1990): 310–12. http://dx.doi.org/10.1093/rheumatology/29.4.310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

HUGHES, R. "SERONEGATIVE ARTHRITIS." Rheumatology 31, no. 11 (1992): 771–72. http://dx.doi.org/10.1093/rheumatology/31.11.771.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

ADEBAJO, A. O. "Dengue Arthritis." Rheumatology 35, no. 9 (1996): 909–10. http://dx.doi.org/10.1093/rheumatology/35.9.909.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Tay, C. H. "Eosinophilic arthritis." Rheumatology 38, no. 12 (December 1999): 1188–94. http://dx.doi.org/10.1093/rheumatology/38.12.1188.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

SHELDON, P. "HLA-B27 RELATED ARTHRITIS, SULPHASALAZINE AND RHEUMATOID ARTHRITIS." Rheumatology 26, no. 5 (1987): 321–24. http://dx.doi.org/10.1093/rheumatology/26.5.321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Hammond, Alison, and Yeliz Prior. "Arthritis glove provision in rheumatoid arthritis and hand osteoarthritis: A survey of United Kingdom rheumatology occupational therapists." Hand Therapy 27, no. 1 (January 5, 2022): 3–13. http://dx.doi.org/10.1177/17589983211060620.

Full text

Abstract:

Introduction Hand pain and function limitations are common in rheumatoid arthritis (RA) and hand osteoarthritis (HOA). Provision of arthritis (compression) gloves to relieve hand symptoms is increasing in occupational therapy. Research evaluating arthritis gloves dates to the 1990s, focussing on night-wear of full-length finger gloves in RA. This survey examined glove provision in contemporary clinical practice in the United Kingdom. Methods A survey of arthritis glove provision in RA was conducted with Royal College of Occupational Therapists Rheumatology Specialist Section members. A more detailed survey about glove provision in RA and HOA was conducted with rheumatology occupational therapists in North-West England. Results Response rates were good, with 60 (73%) therapists responding to the national and 24 (69%) to the regional surveys. Most therapists provided open-finger gloves (commonly IsotonerTM) to about a third of their RA and HOA patients, and to those with any arthritic condition causing significant hand pain and/or swelling. Day-wear was as common as night-wear, and patients were advised to wear these ‘as and when’ for hand symptom relief and support for hand function. They were advised not to wear gloves continually in the day, and regularly perform hand exercises and monitor for potential adverse effects, for example, skin discolouration. Therapists commonly provide replacement gloves as these are often used long-term. Conclusion Prescription of arthritis gloves has changed considerably in the last 30 years, with open-finger gloves provided to a wider range of people with arthritis, for a broader range of clinical reasons.

APA, Harvard, Vancouver, ISO, and other styles

24

Rubinstein, Tamar B., Ekemini A. Ogbu, Martha Rodriguez, Lindsay Waqar, Jennifer M. P. Woo, Alaina M. Davis, William Blaine Lapin, et al. "Prioritized Agenda for Mental Health Research in Pediatric Rheumatology from the Childhood Arthritis and Rheumatology Research Alliance Mental Health Workgroup." Journal of Rheumatology 47, no. 11 (January 15, 2020): 1687–95. http://dx.doi.org/10.3899/jrheum.190361.

Full text

Abstract:

ObjectiveMental health problems are prevalent in youth with rheumatologic disease. Gaps in knowledge exist regarding their effect, as well as strategies for detection and effective treatment. To address these gaps, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Mental Health Workgroup developed and prioritized an agenda of research topics.MethodsWe systematically reviewed the literature and identified 5 major research domains in further need of study: (A) mental health burden and relationship to pediatric rheumatologic disease, (B) effect of mental health disorders on outcomes, (C) mental health awareness and education, (D) mental health screening, and (E) mental health treatment. Research topics within these areas were developed by workgroup leaders and refined by the workgroup. Members were surveyed to prioritize the topics by importance, feasibility of study, and actionability.ResultsFifty-nine members (57%) completed the survey. Among the proposed research topics, 31/33 were rated as highly important and 4/33 were rated highly for importance, feasibility, and actionability. Topics rated most important related to (A) mental health burden and relationship to rheumatologic disease, and (B) the effect of mental health on outcomes. Topics rated most feasible and actionable were related to (D) mental health screening.ConclusionAddressing gaps in knowledge regarding mental health in youth with rheumatologic disease is essential for improving care. We have identified high priority research topics regarding mental health of pediatric rheumatology patients in need of further investigation that are feasible to study and believed to lead to actionable results in patient care.

APA, Harvard, Vancouver, ISO, and other styles

25

Gladman, Dafna. "Gastrointestinal-related arthritis and psoriatic arthritis." Current Opinion in Rheumatology 3, no. 4 (August 1991): 575–80. http://dx.doi.org/10.1097/00002281-199108000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Keat, Andrew. "Reactive arthritis or post-infective arthritis?" Best Practice & Research Clinical Rheumatology 16, no. 4 (September 2002): 507–22. http://dx.doi.org/10.1053/berh.2002.0251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Finckh, Axel. "Early inflammatory arthritis versus rheumatoid arthritis." Current Opinion in Rheumatology 21, no. 2 (March 2009): 118–23. http://dx.doi.org/10.1097/bor.0b013e3283235ac4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hannu, Timo, Robert Inman, Kaisa Granfors, and Marjatta Leirisalo-Repo. "Reactive arthritis or post-infectious arthritis?" Best Practice & Research Clinical Rheumatology 20, no. 3 (June 2006): 419–33. http://dx.doi.org/10.1016/j.berh.2006.02.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Knevel, Rachel, Saskia le Cessie, Chikashi C. Terao, Kamil Slowikowski, Jing Cui, Tom W. J. Huizinga, Karen H. Costenbader, Katherine P. Liao, Elizabeth W. Karlson, and Soumya Raychaudhuri. "Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis." Science Translational Medicine 12, no. 545 (May 27, 2020): eaay1548. http://dx.doi.org/10.1126/scitranslmed.aay1548.

Full text

Abstract:

It is challenging to quickly diagnose slowly progressing diseases. To prioritize multiple related diagnoses, we developed G-PROB (Genetic Probability tool) to calculate the probability of different diseases for a patient using genetic risk scores. We tested G-PROB for inflammatory arthritis–causing diseases (rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathy, psoriatic arthritis, and gout). After validating on simulated data, we tested G-PROB in three cohorts: 1211 patients identified by International Classification of Diseases (ICD) codes within the eMERGE database, 245 patients identified through ICD codes and medical record review within the Partners Biobank, and 243 patients first presenting with unexplained inflammatory arthritis and with final diagnoses by record review within the Partners Biobank. Calibration of G-probabilities with disease status was high, with regression coefficients from 0.90 to 1.08 (1.00 is ideal). G-probabilities discriminated true diagnoses across the three cohorts with pooled areas under the curve (95% CI) of 0.69 (0.67 to 0.71), 0.81 (0.76 to 0.84), and 0.84 (0.81 to 0.86), respectively. For all patients, at least one disease could be ruled out, and in 45% of patients, a likely diagnosis was identified with a 64% positive predictive value. In 35% of cases, the clinician’s initial diagnosis was incorrect. Initial clinical diagnosis explained 39% of the variance in final disease, which improved to 51% (P < 0.0001) after adding G-probabilities. Converting genotype information before a clinical visit into an interpretable probability value for five different inflammatory arthritides could potentially be used to improve the diagnostic efficiency of rheumatic diseases in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

30

Walsh, Jessica A., Shaobo Pei, Zachary Burningham, Gopi Penmetsa, Grant W. Cannon, Daniel O. Clegg, and Brian C. Sauer. "Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance." Journal of Rheumatology 45, no. 3 (November 15, 2017): 430–36. http://dx.doi.org/10.3899/jrheum.170554.

Full text

Abstract:

Objective.To evaluate the effect of access to and distance from rheumatology care on the use of disease-modifying antirheumatic drugs (DMARD) in US veterans with inflammatory arthritis (IA).Methods.Provider encounters and DMARD dispensations for IA (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) were evaluated in national Veterans Affairs (VA) datasets between January 1, 2015, and December 31, 2015.Results.Among 12,589 veterans with IA, 23.5% saw a rheumatology provider. In the general IA population, 25.3% and 13.6% of veterans were exposed to a synthetic DMARD (sDMARD) and biologic DMARD (bDMARD), respectively. DMARD exposure was 2.6- to 3.4-fold higher in the subpopulation using rheumatology providers, compared to the general IA population. The distance between veterans’ homes and the closest VA rheumatology site was < 40 miles (Near) for 55.9%, 40–99 miles (Intermediate) for 31.7%, and ≥ 100 miles (Far) for 12.4%. Veterans in the Intermediate and Far groups were less likely to see a rheumatology provider than veterans in the Near group (RR = 0.72 and RR = 0.49, respectively). Exposure to bDMARD was 34% less frequent in the Far group than the Near group. In the subpopulation who used rheumatology care, the bDMARD exposure discrepancy did not persist between distance groups.Conclusion.Use of rheumatology care and DMARD was low for veterans with IA. DMARD exposure was strongly associated with rheumatology care use. Veterans in the general IA population living far from rheumatology sites accessed rheumatology care and bDMARD less frequently than veterans living close to rheumatology sites.

APA, Harvard, Vancouver, ISO, and other styles

31

Saxena, N., R. Misra, and A. Aggarwal. "Is the enthesitis-related arthritis subtype of juvenile idiopathic arthritis a form of chronic reactive arthritis?" Rheumatology 45, no. 9 (March 7, 2006): 1129–32. http://dx.doi.org/10.1093/rheumatology/kel056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Akil, M., and R. S. Amos. "ABC of Rheumatology: RHEUMATOID ARTHRITIS--II: TREATMENT." BMJ 310, no. 6980 (March 11, 1995): 652–54. http://dx.doi.org/10.1136/bmj.310.6980.652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Galushko, E. A., and A. M. Lila. "«Gastroenterological» rheumatology: differential diagnosis of early arthritis." Modern Rheumatology Journal 13, no. 3 (September 19, 2019): 76–81. http://dx.doi.org/10.14412/1996-7012-2019-3-76-81.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Sandborg, Christy. "The Future of Rheumatology Research: The Childhood Arthritis and Rheumatology Research Alliance." Current Problems in Pediatric and Adolescent Health Care 36, no. 3 (March 2006): 104–9. http://dx.doi.org/10.1016/j.cppeds.2005.10.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Proulx, L., S. Stones, J. Coe, D. Richards, L. Wilhelm, N. Robertson, J. Gunderson, A. Sirois, and A. Mckinnon. "OP0196-PARE #ARTHRITISATWORK: USING TWITTER TO ENGAGE THE INTERNATIONAL ARTHRITIS COMMUNITY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 122. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4793.

Full text

Abstract:

Background:In 2019, EULAR launched the #Time2Work campaign [1] to raise awareness of the impact of rheumatic and musculoskeletal diseases on individuals, society, and the economy. Building on this theme, the Canadian Arthritis Patient Alliance (CAPA) developed a social media campaign and Twitter chat in collaboration with international patient advocates and organizations. The Twitter chat built upon CAPA’s successful development of workplace resources for people living with arthritis [2].Objectives:To deliver an international #ArthritisAtWork social media campaign on Twitter, in support of the #Time2Work campaign.Methods:A one-hour Twitter Chat was held on World Arthritis Day (October 12, 2019) on arthritis in the workplace (#ArthritisAtWork) from 18:00 to 19:00 UTC. The chat was hosted by CAPA and co-hosted by Simon Stones, a patient advocate from the United Kingdom (UK) and CreakyJoints, patient-driven arthritis organization in the United States (US). The Twitter Chat questions were co-developed in advance by the hosts, and blog posts were shared from CAPA’s website. Each host also promoted the Twitter Chat through their websites, newsletters and online communities. A social media analytical tool, Symplur, was used to measure audience engagement using the hashtag #ArthritisAtWork. In addition, pertinent Tweets before, during, and after the chat were obtained. The analysis of themes was undertaken to identify common issues and questions.Results:One hundred and ten users participated in the Twitter chat between 17:20 and 19:20 UTC. Participants included people living with arthritis, researchers, patient organizations, health information outlets and academic institutions. During this period, 565 tweets were shared between participants in Australia, Canada, Ireland, Spain, UK and US. There were 3.352 million Twitter impressions. This represents the number of times a tweet appears to users in either their timeline or search results. Emergent themes of the analysis include:common workplace challenges such as employer attitudes and stigma;effective workplace supports such as prioritizing tasks and requesting workplace accommodations; andareas of improvement such as instituting workplace policies, flexible workplace approaches and education for employees and managers.Conclusion:The social media campaign was successful in reaching a diverse audience and supporting the #Time2Work campaign. Social media tools can provide an important social support for people living with arthritis as they navigate workplace challenges. It also offers a more contemporary platform to engage the international community on issues of common interest. Working together, internationally helps expand reach and reduce barriers in communication. Research can be conducted to measure potential behavior change that leverages digital social support for people living with arthritis.References:[1]EULAR (2019). Press release “EULAR launches Time2Work campaign to highlight the importance of keeping people with rheumatic and musculoskeletal diseases in work. Available from:https://www.eular.org/sysModules/obxContent/files/www.eular.2015/1_42291DEB-50E5-49AE-5726D0FAAA83A7D4/time2work_campaign_press_release_final.pdf2. CAPA (2019). Arthritis in the Workplace: Resources for Patients by Patients. Available from:http://arthritispatient.ca/arthritis-in-the-workplace-resources-for-patients-by-patients/Disclosure of Interests:Laurie Proulx Grant/research support from: Sources of grants and support received by the Canadian Arthritis Patient Alliance (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma., Speakers bureau: I have provided speaking services to Sanofi and Eli Lilly. These engagements do not relate to this abstract., Simon Stones Consultant of: I have been a paid consultant for Envision Pharma Group and Parexel. This does not relate to this abstract., Speakers bureau: I have been a paid speaker for Actelion and Janssen. These do not relate to this abstract., Joseph Coe: None declared, Dawn Richards Grant/research support from: Sources of grants and support received by the Canadian Arthritis Patient Alliance (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma., Consultant of: Dawn has done small consulting projects on patient engagement for companies., Speakers bureau: Dawn has been a paid speaker for several companies., Linda Wilhelm Grant/research support from: Sources of grants and support received by the Canadian Arthritis Patient Alliance (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma., Nathalie Robertson Grant/research support from: Sources of grants and support received by the Canadian Arthritis Patient Alliance (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma., Janet Gunderson Grant/research support from: Sources of grants and support received by the Canadian Arthritis Patient Alliance (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma., Alexandra Sirois Grant/research support from: Sources of grants and support received by the Canadian Arthritis Patient Alliance (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma., Annette McKinnon Grant/research support from: Sources of grants and support received by the Canadian Arthritis Patient Alliance (including in-kind support) in the last two years include: AbbVie Canada, Alliance for Safe Biologic Medicines, Amgen Canada, Arthritis Alliance of Canada, The Arthritis Society, Best Medicines Coalition, CADTH, Canadian Rheumatology Association, Eli Lilly Canada, European League Against Rheumatism, Janssen Canada, Manulife, Novartis Canada, Ontario Rheumatology Association, Pfizer Canada (including Pfizer Hospira), Purdue Pharma Canada, Sanofi, and UCB Pharma.

APA, Harvard, Vancouver, ISO, and other styles

36

Haas, Johannes-Peter, Vincent Weimann, and Eugen Feist. "Polyartikuläre juvenile idiopathische Arthritis und rheumatoide Arthritis." Zeitschrift für Rheumatologie 81, no. 1 (October 28, 2021): 4–13. http://dx.doi.org/10.1007/s00393-021-01114-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Greenblatt, H. Karl, Hyoun-Ah Kim, Leah F. Bettner, and Kevin D. Deane. "Preclinical rheumatoid arthritis and rheumatoid arthritis prevention." Current Opinion in Rheumatology 32, no. 3 (May 2020): 289–96. http://dx.doi.org/10.1097/bor.0000000000000708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Chauhan, S., A. Wakhlu, and V. Agarwal. "Arthritis in leprosy." Rheumatology 49, no. 12 (August 19, 2010): 2237–42. http://dx.doi.org/10.1093/rheumatology/keq264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Short, P., A. C. Jones, D. Walker, A. Kavanaugh, and R. J. Moots. "Working at arthritis." Rheumatology 51, no. 2 (December 16, 2011): 201–3. http://dx.doi.org/10.1093/rheumatology/ker415.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Emery, Paul. "I72. Early Arthritis." Rheumatology 53, suppl_1 (April 2014): i16. http://dx.doi.org/10.1093/rheumatology/keu067.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

DUFF, G. W. "ARTHRITIS AND INTERLEUKINS." Rheumatology 27, no. 1 (1988): 2–5. http://dx.doi.org/10.1093/rheumatology/27.1.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

ROWE, I. F. "AIDS AND ARTHRITIS." Rheumatology 27, no. 6 (1988): 481–82. http://dx.doi.org/10.1093/rheumatology/27.6.481.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

JONES, J. G., J. McCANN, and M. N. LASSERE. "DRIVING AND ARTHRITIS." Rheumatology 30, no. 5 (1991): 361–64. http://dx.doi.org/10.1093/rheumatology/30.5.361.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

AXON, J. M. C., P. R. HAWLEY, and E. C. HUSKISSON. "ILEAL POUCH ARTHRITIS." Rheumatology 32, no. 7 (1993): 586–88. http://dx.doi.org/10.1093/rheumatology/32.7.586.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

GIBSON, T., Q. AHSAN, and K. HUSSEIN. "ARTHRITIS OF LEPROSY." Rheumatology 33, no. 10 (1994): 963–66. http://dx.doi.org/10.1093/rheumatology/33.10.963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

CUTOLO, M. "Tenascin and Arthritis." Rheumatology 33, no. 2 (1994): 197–98. http://dx.doi.org/10.1093/rheumatology/33.2.197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

MISRA, R., K. DARTON, R. F. JEWKES, C. M. BLACK, and R. N. MAINI. "ARTHRITIS IN SCLERODERMA." Rheumatology 34, no. 9 (1995): 831–37. http://dx.doi.org/10.1093/rheumatology/34.9.831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Walsh, D. "Angiogenesis and arthritis." Rheumatology 38, no. 2 (February 1, 1999): 103–12. http://dx.doi.org/10.1093/rheumatology/38.2.103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Toivanen, A. "Managing reactive arthritis." Rheumatology 39, no. 2 (February 2000): 117–19. http://dx.doi.org/10.1093/rheumatology/39.2.117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Girard, F. "Health-care use by rheumatoid arthritis patients compared with non-arthritic subjects." Rheumatology 41, no. 2 (February 1, 2002): 167–75. http://dx.doi.org/10.1093/rheumatology/41.2.167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!